Cardinal Analytx, which develops predictive analytics software for health care payers and providers, raises $22M Series B led by Kleiner Perkins' John Doerr
Kyle Wiggers / VentureBeat :
Context & Ripple Effects
Cardinal Analytx's round lands mid-wave in a busy 2019 for healthcare AI financing: months earlier, Health Catalyst pulled in $100M at a $1B valuation for AI-driven data storage and analytics, and January saw CarePredict raise a $9.5M Series A for senior-care prediction. The difference here is who signed the check — John Doerr personally leading a Series B is a marquee-name bet on the payer/provider prediction layer specifically.
The round also positions Cardinal Analytx ahead of the next cohort: by early 2020, [[a:951350|Health Data Analytics Institute raised $16M to productize its outcome-prediction service as an API]], suggesting the category Doerr backed was about to get more crowded and more infrastructure-like.
First-order effects
- Cardinal Analytx gains $22M and Doerr's direct involvement to scale its predictive analytics software across health care payers and providers.
- Kleiner Perkins adds a healthcare AI position to its portfolio with its chairman-level partner personally attached, raising the firm's visibility in the sector.
Second-order effects
- Better-funded rivals force incumbents like Health Catalyst — already valued at $1B on the data-and-analytics side — to defend their payer/provider accounts against a prediction-focused challenger.
- Payers and providers evaluating predictive tools gain negotiating leverage as funded entrants multiply, pressuring pricing across the prediction-software layer.
Third-order effects
- If the funding cadence holds — Health Catalyst on storage, Cardinal Analytx on prediction, HDAI moving to APIs — healthcare AI splits into a data-infrastructure tier and an application tier, with capital favoring whichever layer owns the customer relationship.
- A wave of well-capitalized point-solution predictors sets up eventual consolidation, as payers and providers rationalize overlapping AI vendors into fewer platform relationships.
The trend: Healthcare AI venture funding is shifting from general data platforms toward specialized outcome-prediction vendors, with top-tier investors making personal, name-brand bets on the application layer.